Sign in
Taking people in United StatesPhase 2

Tests 2-HOBA in people with long COVID and POTS

Tests 2-HOBA against placebo in adults with long COVID and POTS.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Registry title
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
18 Dec 2025
Expected to end
30 Jun 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • To Measure levels of circulating monocyte/ T cell doublets at Baseline
  • To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
  • To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
  • To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
  • To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo
  • To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA
  • To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
Record updated
22 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have both Long COVID and POTS (a condition where the heart rate rises too much on standing). It tests 2-HOBA against a placebo.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Long COVID symptoms lasting more than 3 months after a SARS-CoV-2 infection, plus POTS (heart rate rising over 30 bpm or above 120 bpm on standing, with symptoms lasting more than 3 months). The POTS diagnosis must be confirmed with standing vital signs before enrollment.
Earlier treatment
People cannot join if they use steroids or other immune therapies, central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), or monoamine oxidase inhibitors (MAO-I).
Biomarker or test result
A past SARS-CoV-2 infection from 3 or more months ago, shown by symptoms, contact with a case, a positive test, or a note from a health care provider.

Main reasons for not taking part

  • Active SARS-CoV-2 infection (within 4 weeks of onset)
  • Moderate or severe weakened immune system, or known autoimmune disease
  • Known heart or blood vessel disease, or uncontrolled high blood pressure
  • Type 1 or type 2 diabetes, or poor liver or kidney function
  • Pregnant or breastfeeding women, or aspirin allergy

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • All participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:
  • Long COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection
  • POTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt
  • For patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study
  • 2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study
  • SARS-CoV-2 infection 3 or more months prior identified by the follow signs:
  • Meets the clinical OR epidemiological criteria
  • Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia
  • Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test
  • A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND/OR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test
  • Documented by health care provider in clinical note or encounter

Who cannot take part

  • Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),
  • Known active acute SARS-Cov-2 infection (4 weeks from onset)
  • Uncontrolled hypertension (BP>140/90 despite appropriate treatment)
  • Type 1 or type 2 diabetes mellitus
  • Known history of autoimmune disease, steroid use or other immunotherapies,
  • Inability to provide informed consent; We will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA; -
  • Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg/dl),
  • Impaired renal function test (eGFR<60 mL/min/1.73m2),
  • Anemia (hemoglobin <10 g/dl),
  • Moderate or severe immunocompromised patients,
  • Pregnant or breastfeeding women,

Where in United States

  • Cyndya ShibaoNashville, United StatesContact: Marwa Mohamed, PhdTaking people

About the trial

What the trial wants to find out

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.

Read full original descriptionShow less

Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.

Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.

The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo

The 3 groups in the trial

  • Levels of circulating monocyte/ T cell doublets, and inflammatory cytokines in 2 HoBA Vs PlaceboPlacebo, for comparison

    to test the effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo on circulating monocyte/ T cell doublets (CD14+CD3+) , and inflammatory cytokines

    Treatment: To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, and To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment

  • Effect of 2HOBA on Splanchnic venous capacitance and compare with placebo group on POTS patientsPlacebo, for comparison

    To test the hypothesis that IsoLG-adducts directly contribute to splanchnic vasodilation, by assessing changes in splanchnic venous capacitance with 2-HOBA treatment at head up Tilt

    Treatment: To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo

  • Effect of 2HOBA on Orthostatic Tachycardia compare with placebo group during 30 minutes head up tiltExisting treatment, for comparison

    To test that IsoLG-adducts directly effect Orthostatic tachycardia in LCPOTS, during 30-minute head-up tilt.

    Treatment: To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA and To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS
Plain-language title
Tests 2-HOBA in people with long COVID and POTSGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 January 2026